FDA Takes a Step Toward Harm Reduction but Still Has Work to Do

The U.S. Food and Drug Administration (FDA) has granted authorization of flavored vaping products for the first time in the U.S. The agency’s decision on products in flavors beyond tobacco and menthol, including mango and blueberry, marks a significant step forward for public health and taxpayers saving millions of dollars in lower healthcare costs. Even more notably, the FDA has explicitly acknowledged in a press release that vaping products are “less harmful alternatives” to combustible cigarettes. That admission represents a long overdue recognition of the role these products can play in reducing smoking related disease and death.

However, this progress did not happen easily and took way too long. According to reporting in The Wall Street Journal, President Donald Trump pressured FDA Commissioner Marty Makary to move forward on long delayed approvals. This raises the uncomfortable question as to why it took political intervention to push through a decision that aligns with the scientific evidence. The process had already stalled for far too long in the first place.

There appears to be an issue within the regulatory system which needs to be resolved. For years, the FDA has exercised extreme caution when it comes to nicotine alternatives, often influenced by a combination of institutional risk aversion and pressure from prohibitionist advocacy groups. While caution is understandable in matters of public health, excessive delay carries its own costs. Every year that safer alternatives are held back is another year in which millions of Americans continue smoking cigarettes, the most dangerous form of nicotine consumption.

The evidence on flavored vaping products is particularly clear. Research consistently shows that non tobacco flavors play a crucial role in helping adult smokers transition away from cigarettes. By authorizing flavored products, the FDA has taken an important step toward making harm reduction a practical reality, with all the benefits that come with it. Yet, the pace of progress remains frustratingly slow. To date, the agency has authorized only a few dozen vaping products, while thousands of other alternatives remain in regulatory limbo.

That blockage has real world consequences. Limited legal availability does not eliminate demand. Instead, it pushes consumers toward unregulated markets, where products are sold without quality controls or age restrictions. Ironically, the FDA’s restrictive approach may have contributed to the very youth access issues it is trying to prevent. A more open and regulated market would make it easier to control product standards and restrict underage sales, while giving adult smokers access to safer options.

At the same time, the FDA’s approach to newly authorized products raises additional concerns. Some of the devices include advanced age verification technologies, such as ID checks, smartphone pairing, and biometric authentication. While these measures are intended to prevent youth use, they may also create unnecessary barriers for adult smokers, particularly older individuals who are less comfortable with complex technology. These are the very people who stand to benefit most from switching away from cigarettes, yet they may be deterred by overly burdensome requirements.

This reflects a broader imbalance in regulatory priorities. The FDA has placed enormous emphasis on preventing youth vaping, often treating it as the central issue. While protecting young people is important, it should not come at the expense of addressing the far greater harm caused by adult smoking. Youth experimentation with vaping is typically experimental and unlikely to produce the same long term health consequences as decades of cigarette use. By contrast, older smokers face immediate and serious risks, and they need accessible, appealing alternatives immediately.

The agency’s evolving stance suggests that change may finally be underway. Officially recognizing vaping as a less harmful alternative is a welcome shift in tone, and authorizing flavored products signals a willingness to match policy more closely with scientific evidence. But this should be seen as just a starting point. The FDA must now build on this momentum by accelerating approvals, expanding the range of available products, and removing unnecessary barriers that limit access for adult smokers.

Millions of Americans still smoke, and many are seeking effective ways to quit or reduce their risk. Safer nicotine products, including vaping devices, heated tobacco products, and nicotine pouches, offer a pathway to achieve that goal. The science supporting harm reduction is no longer in doubt. What is needed now is a regulatory framework that reflects that reality with urgency and confidence.

The FDA’s latest decision is a welcome and important breakthrough. But if it is to truly transform public health, it must be followed by a significant shift in mindset. Reducing smoking related disease should be the central objective, and that means making safer alternatives not just available, but also accessible and appealing to the people who need them most.

Martin Cullip is an International Fellow at The Taxpayers Protection Alliance’s Consumer Center and is based in South London, UK.